Sugi Predict

Sugi Predict / Compounds / SCHEMBL3364543

SCHEMBL3364543

SCHEMBL3364543

O=S(=O)(Cl)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.68
▸ CA2 P00918 2/20 0.68
▸ KIF11 P52732 8/20 0.61
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ EPHX2 P34913 1/20 0.50
▸ PTPN11 Q06124 1/20 0.48
▸ ALOX15 P16050 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MAPT P10636 2/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ AR P10275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26422694 0.83 CA1 (0.68) CA1CA2KIF11MEN1KMT2A
SCHEMBL27826397 0.81 CA1 (0.66) CA1CA2KIF11MEN1KMT2A
SCHEMBL13656086 0.81 KIF11 (0.89) CA1CA2KIF11MEN1KMT2A
SCHEMBL1645153 0.81 CA1 (1.00) CA1CA2KIF11CA12CA9
SCHEMBL11121097 0.81 PTPN11 (0.72) CA1CA2KIF11MEN1KMT2A
SCHEMBL14601685 0.79 MEN1 (0.65) CA1CA2KIF11MEN1KMT2A
SCHEMBL4039522 0.79 CA1 (0.63) CA1CA2KIF11MEN1KMT2A
SCHEMBL1615445 0.77 ALDH1A1 (0.50) CA1CA2MEN1KMT2AMAPK1
SCHEMBL3380022 0.76 KIF11 (1.00) CA1CA2KIF11
SCHEMBL5531754 0.76 KIF11 (1.00) CA1CA2KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382270-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2025-12-18 — — US disclosed
US-20250340514-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2025-11-06 — — US disclosed
US-12398103-B2 3-diarylmethylenes and uses thereof ATUX ISKAY LLC (US) 2025-08-26 — — US disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 — — US disclosed
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC 2023-05-11 — — US disclosed
US-20230129040-A1 IMMUNOMODULATING AZALIDES ZOETIS SERVICES LLC 2023-04-27 — — US disclosed
US-20230129040-A1 IMMUNOMODULATING AZALIDES ZOETIS SERVICES LLC 2023-04-27 — — US disclosed
EP-4121031-A1 3-DIARYLMETHYLENES AND USES THEREOF Atux Iskay LLC (US) 2023-01-25 — — EP disclosed
WO-2021188949-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2021-09-23 — — WO disclosed
WO-2021188949-A1 3-DIARYLMETHYLENES AND USES THEREOF ATUX ISKAY LLC (US) 2021-09-23 — — WO disclosed
EP-1358162-A1 DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-05 — — EP disclosed
EP-1311475-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-05-21 — — EP disclosed
EP-1303503-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 — — EP disclosed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 — — WO disclosed
US-20030004156-A1 Dihydroindole and tetrahydroquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-01-02 — — US disclosed
WO-2002050041-A1 DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-27 — — WO disclosed
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 — — US disclosed
US-20020038025-A1 Analine derivatives as OSC inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-03-28 — — US disclosed
WO-2002014267-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-21 — — WO disclosed
WO-2002006189-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382270-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 CA1 4607/4885CA2 4322/4885KIF11 3091/4885
US-12398103-B2 3-diarylmethylenes and uses thereof MYC, MYCBP, FOXO1 CA1 4607/4885CA2 4322/4885KIF11 3091/4885
US-20250340514-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 CA1 4607/4885CA2 4322/4885KIF11 3091/4885
US-20230146127-A1 3-DIARYLMETHYLENES AND USES THEREOF MYC, MYCBP, FOXO1 CA1 4607/4885CA2 4322/4885KIF11 3091/4885
US-20230129040-A1 IMMUNOMODULATING AZALIDES IL2, MALT1, FCGRT CA1 1803/4885CA2 3281/4885KIF11 2799/4885
US-20030004156-A1 Dihydroindole and tetrahydroquinoline derivatives CYP46A1, LSS, CYP51A1 CA1 2837/4885CA2 2617/4885KIF11 4116/4885
US-20020038025-A1 Analine derivatives as OSC inhibitors LSS, CYP51A1, CYP46A1 CA1 1870/4885CA2 3023/4885KIF11 4709/4885
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 CA1 2475/4885CA2 2022/4885KIF11 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.